Rehůrek J, Vancurová J
Klinika dĕtské oftalmologie FDN a LF MU, Brno, CSc.
Cesk Slov Oftalmol. 1998 Apr;54(2):82-5.
The authors investigated in a group of six children with glaucoma persisting for a long time the possibility to use locally applied carbonic anhydrase inhibitor, 2% dorsolamide hydrochloride in the form of eye drops (TRUSOPT, Merck Co.). In the submitted preliminary study they evaluate the effectiveness of the drug in glaucoma in children very favourably, previous essential treatment with oral acetazolamide could be discontinued in all patients without a deleterious effect. The authors did not encounter any undesirable effects of the drug nor manifestations of intolerance calling for discontinuation of TRUSOPT treatment. This is so far the first communication on TRUSOPT treatment of child glaucoma in the available literature.
作者对一组6名患有长期青光眼的儿童进行了研究，探讨局部应用碳酸酐酶抑制剂——2%盐酸多佐胺滴眼液（TRUSOPT，默克公司）的可能性。在提交的初步研究中，他们对该药物治疗儿童青光眼的有效性评价很高，所有患者此前使用口服乙酰唑胺的必要治疗均可停用，且无有害影响。作者未发现该药物有任何不良影响，也没有出现需要停用TRUSOPT治疗的不耐受表现。这是目前现有文献中关于TRUSOPT治疗儿童青光眼的首篇报道。
